Avalon Pharmaceuticals to Ring the NASDAQ Closing Bell on March 27, 2006
March 23 2006 - 9:00AM
PR Newswire (US)
GERMANTOWN, Md., March 23 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (Nasdaq and ArcaEx(R): AVRX), a
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics, today announced that Kenneth C.
Carter, Ph.D., President and CEO of Avalon Pharmaceuticals, will
preside over The NASDAQ Stock Market Closing Bell at 4:00 p.m.
Eastern Time on Monday March 27, 2006. "Our debut as a
NASDAQ-listed company this past September marked a milestone of
which we are very proud and we are pleased to celebrate it at the
Closing Bell ceremony at NASDAQ," stated Kenneth C. Carter, Ph.D.,
President and CEO of Avalon. Web Cam: To view the live Closing
Bell, visit http://www.nasdaq.com/reference/marketsite_about.stm
and follow the instructions below: - Scroll to the bottom of the
page under the heading MarketSite Live Web cam and click on Windows
Media Player. - Viewers should download the web cam at 3:45 p.m.
Eastern Time in order to have time to trouble-shoot in case of
technical difficulties. Broadcast Feed: The closing bell is
available from 3:50 to 4:05 p.m. on uplink IA-6 C-band /
transponder 17. The downlink frequency is 4040 Vertical; audio:
6.2-6.8. The feed can also be found on Waterfront fiber 1623. About
Avalon Pharmaceuticals, Inc. Avalon Pharmaceuticals is a
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics for the treatment of cancer. Avalon
seeks to discover and develop novel therapeutics through the use of
a comprehensive, innovative and proprietary suite of technologies
based upon large-scale gene expression analysis which it calls
AvalonRx(R). This platform facilitates drug discovery by expanding
the range of therapeutic targets for drug intervention, including
targets and target pathways frequently considered intractable using
conventional HTS approaches, allows more informed decisions about
which compounds to advance towards clinical trials, and facilitates
drug development through identification of biomarkers of efficacy
that can stratify patients or provide early indicators of response.
Avalon Pharmaceuticals was established in 1999 and is headquartered
in Germantown, Maryland. Contacts: Avalon Pharmaceuticals, Inc.
Noonan Russo Gary Lessing Wendy Lau (Media) Executive Vice
President and CFO Tel: (212) 845-4272 Tel: (301) 556-9900 Fax:
(301) 556-9910 Jane Petrino (Investors) Email: Tel: (212) 845-4274
DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing,
Executive Vice President and CFO of Avalon Pharmaceuticals, Inc.,
+1-301-556-9900, Fax +1-301-556-9910, ; or Wendy Lau - Media,
+1-212-845-4272, or Jane Petrino, Investors, +1-212-845-4274, both
of Noonan Russo for Avalon Pharmaceuticals, Inc. Web site:
http://www.nasdaq.com/reference/marketsite_about.stm
Copyright